These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 36388082)

  • 41. Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.
    Alamri H; Patterson NH; Yang E; Zoroquiain P; Lazaris A; Chaurand P; Metrakos P
    Anal Bioanal Chem; 2019 Feb; 411(4):885-894. PubMed ID: 30515538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression.
    Li X; Yuan B; Lu M; Wang Y; Ding N; Liu C; Gao M; Yao Z; Zhang S; Zhao Y; Xie L; Chen Z
    Nat Commun; 2021 Dec; 12(1):7213. PubMed ID: 34893641
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.
    De A; Duseja A
    J Clin Exp Hepatol; 2020; 10(3):255-262. PubMed ID: 32405182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress.
    Li BH; He FP; Yang X; Chen YW; Fan JG
    Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD36 as a Molecular Target of Functional DNA Aptamer NAFLD01 Selected against NAFLD Cells.
    Pu Y; Xiang J; Zhang X; Deng Y; Liu H; Tan W
    Anal Chem; 2021 Mar; 93(8):3951-3958. PubMed ID: 33596054
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms.
    Heinle JW; DiJoseph K; Sabag A; Oh S; Kimball SR; Keating S; Stine JG
    Nutrients; 2023 May; 15(11):. PubMed ID: 37299416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatic DKK1-driven steatosis is CD36 dependent.
    Yang Z; Huang X; Zhang J; You K; Xiong Y; Fang J; Getachew A; Cheng Z; Yu X; Wang Y; Wu F; Wang N; Feng S; Lin X; Yang F; Chen Y; Wei H; Li YX
    Life Sci Alliance; 2023 Jan; 6(1):. PubMed ID: 36410795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
    Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
    J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
    Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
    Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Naringin improves lipid metabolism in a tissue-engineered liver model of NAFLD and the underlying mechanisms.
    Zhang X; Zhang Y; Gao W; Guo Z; Wang K; Liu S; Duan Z; Chen Y
    Life Sci; 2021 Jul; 277():119487. PubMed ID: 33862107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coagulation Factor VII Fine-tunes Hepatic Steatosis by Blocking AKT-CD36-Mediated Fatty Acid Uptake.
    Zhang Y; Jiang Q; Liang X; Qian Q; Xiong J; Liu C; Xu J; Wang N; Xu Y; Zhou P; Lu S; Zhou Q; Yuan Y; Fan X; Liu J; Chen S
    Diabetes; 2024 May; 73(5):682-700. PubMed ID: 38394642
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dietary sucrose regulates the expression of the Cd36 gene in hepatic tissue of rats with obesity and Non Alcoholic Fatty Liver Disease (NAFLD).
    Castro RQ; Soto Rodriguez I; Deschamps Lago RA; Pagola PG; Rodriguez Antolin J; Peres Quintal A; Rivera JR; Aguilera AA
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Jun; 162(2):99-106. PubMed ID: 29765172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current Options and Future Directions for NAFLD and NASH Treatment.
    Zhang C; Yang M
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liver transplantation and non-alcoholic fatty liver disease.
    Zezos P; Renner EL
    World J Gastroenterol; 2014 Nov; 20(42):15532-8. PubMed ID: 25400437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease.
    Sheedfar F; Sung MM; Aparicio-Vergara M; Kloosterhuis NJ; Miquilena-Colina ME; Vargas-Castrillón J; Febbraio M; Jacobs RL; de Bruin A; Vinciguerra M; García-Monzón C; Hofker MH; Dyck JR; Koonen DP
    Aging (Albany NY); 2014 Apr; 6(4):281-95. PubMed ID: 24751397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH).
    Murphy WA; Adiwidjaja J; Sjöstedt N; Yang K; Beaudoin JJ; Spires J; Siler SQ; Neuhoff S; Brouwer KLR
    Clin Pharmacol Ther; 2023 Feb; 113(2):275-297. PubMed ID: 35429164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease.
    Ni M; Zhang B; Zhao J; Feng Q; Peng J; Hu Y; Zhao Y
    Biomed Pharmacother; 2019 May; 113():108778. PubMed ID: 30897538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.